Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of PF-06801591 with or without BCG in high-risk non-muscle invasive bladder cancer
CTR20202139Phase 3Active
- Sponsor
- Pfizer
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sasanlimab, bcg vaccine in non-muscle-invasive bladder cancer (NMIBC), transitional cell carcinoma of the bladder (TCC), sponsored by Pfizer. Started Dec 2020; status: active.
02
Drugs
sasanlimabbcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on CTR20202139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202139.